Nordion Inc (NDN.TO)

BUY
Good long term holding.
DON'T BUY
Well managed. Good return on earnings. Concerns on Proteomics in the short term.
BUY
Earnings down because they bought back proteomics IPO shares. Good company.
DON'T BUY
Has some problems. Europe operation not right yet. Didn't meet expectations. Good long term hold. Wait
TOP PICK
Has some very solid assets with potential for good growth.
BUY
Good way to invest in bio techs.
BUY
Great combination of lab work and genomics. Good price.
PAST TOP PICK
(Was a top pick on Jul 11/00 down 5.5%) Long term OK, but valuations are rich right now.
BUY
Likes. Good mngmnt. Well diversified in biotechs. A good buy in low to mid $20's.
BUY
Technically weak, but could recover when Cdn government increases health care. Also expect Henmasol will turn out to be a very strong asset.
BUY
All bad news is out, so at a good price now. Good potential on their projects.
BUY
Good growth prospects. At a good price.
WAIT
Twice book value. Earnings estimate down.
BUY
A good time to get in. Stable cash flow from labs and good growth prospects.
BUY
Very low. Didn't sell IPO which turned off investors. A world class company.
Showing 166 to 180 of 229 entries